Finesand, glad you mentioned the $200MM of "anti-body inventory" (assume it is sale value at the $70K price point), which to my knowledge is not reflected in the Financials as an Asset. Paraphrasing Dr RP - buying at current share price was like getting the technology and development assets for free. If I misunderstood his comments, please correct. Thanks.